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Abstract
Background: Pulmonary tuberculosis (TB) in people living with HIV (PLH) frequently presents as sputum smear-
negative. However, clinical trials of TB in adults often use smear-positive individuals to ensure measurable bacterial
responses following initiation of treatment, thereby excluding HIV-infected patients from trials.
Methods: In this prospective case cohort study, 118 HIV-seropositive TB patients were assessed prior to initiation of
standard four-drug TB therapy and at several time points through 35 days. Sputum bacillary load, as a marker of
treatment response, was determined serially by: smear microscopy, Xpert MTB/RIF, liquid culture, and colony counts
on agar medium.
Results: By all four measures, patients who were baseline smear-positive had higher bacterial loads than those
presenting as smear-negative, until day 35. However, most smear-negative PLH had significant bacillary load at
enrolment and their mycobacteria were cleared more rapidly than smear-positive patients. Smear-negative patients’
decline in bacillary load, determined by colony counts, was linear to day 7 suggesting measurable bactericidal
activity. Moreover, the decrease in bacterial counts was comparable to smear-positive individuals. Increasing cycle
threshold values (Ct) on the Xpert assay in smear-positive patients to day 14 implied decreasing bacterial load.
Conclusion: Our data suggest that smear-negative PLH can be included in clinical trials of novel treatment
regimens as they contain sufficient viable bacteria, but allowances for late exclusions would have to be made in
sample size estimations. We also show that increases in Ct in smear-positive patients to day 14 reflect treatment
responses and the Xpert MTB/RIF assay could be used as biomarker for early treatment response.
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Introduction
In high tuberculosis (TB) burden settings HIV-infection
confers markedly higher risk of TB infection and TB dis-
ease [1]. In general, pulmonary TB in persons living with
HIV (PLH) presents with less cavitation and lower bacil-
lary loads in sputum [2–6] and is therefore more likely
to be below the detection limit of smear microscopy
than in immunocompetent individuals [7]. Inclusion cri-
teria for clinical trials of novel agents or regimens
against TB often require smear-positive disease to assure
baseline positive Mycobacterium tuberculosis cultures in
samples taken prior to initiation of TB treatment to en-
sure measurable treatment responses from a high base-
line [8, 9]. Smear-negative PLH are therefore
underrepresented in studies of novel treatments for pul-
monary TB [10–13].
Four semi-quantitative methods are used to infer ba-
cillary load - the concentration of mycobacteria - in a
biological sample [14–20]. Smear grading on Ziehl-
Nielsen or auramine stained smears directly detects bac-
teria by light or fluorescent microscopy [14]. The Xpert
MTB/RIF assay (Cepheid Innovation, Sunnyvale, CA) is
based on nucleic acid amplification technology (NAAT)
[15]. It has a reported limit of detection (LOD) of as low
as 112.6 CFU/ ml (colony forming units per millilitre)
and is increasingly replacing smear microscopy as the
primary diagnostic measure on sputum from individuals
with presumptive pulmonary TB [16–18]. Subsequently,
the Xpert MTB/RIF-Ultra assay has become available
that has a reported LOD of 15.6 CFU/ml [19]. The
Xpert’s cycle threshold (Ct or Cq) reflects bacillary load
as an inverse measure, where low values represent high
bacillary numbers. The fluorescent signal produced from
the NAAT emerges sooner if more DNA is present and
in practice, those with M. tuberculosis detected results
have Ct values from 15 to 28. In the automated Myco-
bacterial Growth Indicator Tube (MGIT) liquid culture
system (Becton, Dickinson, Franklin Lakes, NJ), the
time-to-positive (TTP) signal occurs sooner when bacil-
lary load is high [20]. Positive results are detected from
as low as 3 days with high loads but the system can flag
positive to up to 42 days, after which it is considered
negative. Bacterial cell counts on solid media provide
numeric read outs and viable bacillary load can be quan-
tified accurately. Cultures - although providing evidence
of mycobacterial viability, which smear microscopy and
Xpert are unable to do - may not be of immediate value
because positive results for bacterial cell counts take at
least 3 weeks for bacteria to form colonies, and MGIT
culture can take up to 42 days for a positive result [14]
by which time decisions about initiating TB treatment
likely have already been made. Withholding treatment in
patients potentially eligible for a clinical trial for the cul-
ture results would be unacceptable.
In this study we followed a cohort of adult PLH with
pulmonary TB, both smear-negative and smear-positive,
and subjected their serial sputum specimens whilst on
therapy to these four semi-quantitative methods to char-
acterise their initial, and extended mycobacterial re-
sponses to TB treatment. Our overall objective was to
assess if HIV-infected, smear-negative patients with pul-
monary TB have demonstrable bacillary responses to




This was a three site, prospective case cohort study,
in which we purposively recruited HIV-infected adult
TB patients irrespective of their antiretroviral therapy
status. After obtaining informed consent, adult pa-
tients with an initial public sector Xpert positive re-
sult were recruited at Soweto, Klerksdorp and Cape
Town - into two studies with almost identical design.
Patients were included if they had not taken TB med-
ications in the 1 year prior to enrolment and were eli-
gible for standard four-drug first-line TB regimen for
the current TB disease episode. Patients were ex-
cluded if they had received more than 5 days of TB
treatment before the first study sputum was taken,
and if they had received any antibiotics with activity
against M. tuberculosis in the previous 10 days (e.g.
aminoglycosides, fluoroquinolones, etc.). Standard
four-drug anti-TB therapy was initiated as soon as
possible after: 2 months of isoniazid, rifampicin, pyra-
zinamide, and ethambutol, followed by 4 months of
isoniazid and rifampicin (2HRZE/4HR). Patients were
referred for antiretroviral therapy (ART) initiation if
not already started, according to then-current national
guidelines. Patients with drug resistant TB or in need
of specialized TB treatment were not eligible, but
were referred to an appropriate clinic. Socio-
demographic data; prior episodes of TB; recent or
current exposure to other anti-TB drugs; smoking
and alcohol habits; occupational mining and dust ex-
posure history; and antiretroviral treatment history
were collected. Baseline patient measurements and in-
vestigations included: weight; height; chest x-ray; spot
and/or overnight study sputum; CD4 count; viral load
and full blood count. Sputum samples were collected
from participants at baseline and then after initiation
of drug therapy, at days 3, 7, 14, 28 and 35. In this
analysis, data from day 28 (21 patients) and day 35
(84 patients) were combined, and designated as the
“day 35” time point. For patients who missed time
points due to loss to follow up, or for other reasons,
earlier time points were included.
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Quantification of mycobacteria
All specimens were processed and analysed in research
laboratories. Standard diagnostic tests were performed
on decontaminated sputum samples according to the
South African National Health Laboratory Service
(NHLS) guidelines: smear microscopy by auramine O
stain, Xpert and MGIT. In addition the number of col-
ony forming units were determined on Middlebrook
7H11 agar medium supplemented with 0.5% OADC
(oleic acid, albumin, dextrose, catalase, Becton Dickin-
son, South Africa) and documented as the logarithm of
the colony forming units per millilitre (logCFU) [21],
counting duplicate 10-fold serial dilutions series.
Data analysis
This was an exploratory descriptive study and a sample
of 118 patients was included, anticipating that baseline
smear status of the entire group would be similarly
represented. For each patient attending a study visit, all
four semi-quantitative assays were performed on sputum
and outputs were given as: auramine smear grade for
microscopy, MTB grading and Ct values as supplied by
standard Xpert documentation, TTP for MGIT and
logCFU for viable counts. Continuous data were re-
ported as medians and interquartile ranges for Xpert,
MGIT and bacterial load. Negative results were docu-
mented for Xpert as a Ct of 40, for MGIT as a TTP of
42 days and for viable counts as logCFU = 0. For analysis
of discrete data, positive results for microscopy were re-
corded according to auramine grading (AU): scanty
(AUSC), one plus positive (AUP1+), two plus positive
(AUP2+), or three plus positive (AUP3+); Xpert was
given as MTB detected (MTBD) at a Ct of < 36; MGIT
as TTP < 42 days and viable counts as logCFU > 0. Early
bactericidal activity (EBA) is the fall in viable counts/ml
sputum/day, calculated from colony forming units on
Table 1 Baseline characteristics stratified by smear status
Variable Overall Smear positive Smear negative P-value
Enrolment 118 77 41 –
Gender
Female (%) 60 (50.85) 43 (55.84) 17 (41.46) 0.1368
Male (%) 58 (49.15) 34 (44.16) 24 (58.54)
Median age (IQR) in years 35.0 (31.0–42) 36.0 (31.0–42) 34.0 (29.5–43) 0.2595
Median CD4 count (IQR) 137 (11.0–274) 141 (0.00–272) 82.5 (20.0–274) 0.8428
BMIa
Underweight (%) 31 (27.19) 22 (29.33) 9 (23.08) 0.6257
Normal (%) 66 (57.89) 41 (54.67) 25 (64.10)
Overweight/Obese (%) 17 (14.91) 12 (16.00) 5 (12.82)
Median BMI (IQR) 20.0 (18.3–22.7) 19.9 (18.0–22.7) 20.4 (18.6–22.8) 0.8018
Cavitiesa
No (%) 36 (50.00) 16 (36.36) 20 (71.43) 0.0037
Yes (%) 36 (50.00) 28 (63.64) 8 (28.57)
Homeless within past yeara
No (%) 81 (98.78) 51 (100.0) 30 (96.77) –
Yes (%) 1 (1.22) 0 (0.00) 1 (3.23)
Not employed within the past 12monthsa
No (%) 44 (53.66) 30 (58.82) 14 (45.16) 0.2290
Yes (%) 38 (46.34) 21 (41.18) 17 (54.84)
Alcohol use within the past year?a
No (%) 39 (47.56) 26 (50.98) 13 (41.94) 0.4265
Yes (%) 43 (52.44) 25 (49.02) 18 (58.06)
Did you smoke at least 2 cigarettes a week in the past month
No (%) 87 (73.73) 58 (75.32) 29 (70.73) 0.5893
Yes (%) 31 (26.27) 19 (24.68) 12 (29.27)
IQR Interquartile range
aTotals may not be equal to the sample size as a result of missing values
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solid medium at given time points. Data were analysed
using GraphPad Prism 8. Comparison of continuous
data was conducted by the Kruskal-Wallis method (non-
parametric) or the students t-test (parametric). The dif-
ference in slope comparisons was estimated using linear
mixed modelling.
Results
Patient demographics and clinical characteristics
From August 2013 to August 2014, we recruited 118
HIV-infected adults with pulmonary TB as evidenced by
hard copy of a positive Xpert result taken routinely at a
public sector clinic. At baseline, all patients were classi-
fied by the study smear result (Table S1): 41 (35%) were
smear-negative and the other 77 (65%) smear-positive.
Median age was 34 and 36 years, 19 and 22 kg / m2 for
body mass index (BMI) and 82 and 141 cells / mm3 for
CD4 count, in smear-negative and smear-positive pa-
tients, respectively. They differed significantly only by
proportion of cavitation on chest x-ray: 28.6% of the
smear-negative and 63% of smear-positive patients
(Table 1).
Accuracy of smear status at baseline
Overall, at baseline, higher smear status reflected lower
Ct values (Fig. 1). However, of the 41 patients that were
smear-negative (AUNEG), 27 (65.9%) were positive by
Xpert diagnosis (Table S1); of these, the Ct values
ranged between 16.2 and 33. In smear-positive patients
(AUPOS) Ct values ranged between and 11.0 and 30.2.
At baseline, 23 (85.2%) and 63 (96.9%) of smear-negative
and smear-positive patients, respectively, were MGIT
positive for M. tuberculosis. Of the culture negative sam-
ples, 14 (34.1%) also had a baseline negative Xpert result.
Importantly, all participants, irrespective of smear status
had at least one positive culture result during the study
(MGIT and/or colony count culture).
Response to therapy
Standard four-drug TB treatment resulted in rapid reduc-
tions in all measures of bacillary load in both smear-
negative and smear-positive groups (Fig. 2a – d). More-
over, at every time point, the four measures from the
smear-positive patients had a higher percentage of positive
results than from the smear-negative patients. Difference
in slope by baseline smear status for the proportion that
remained positive was statistically significant for all three
measures (p < 0.001 on each comparison). By day 35 spu-
tum specimens were positive in smear-negative and
smear-positive patients, respectively in 11.1 and 28.6% by
smear, 47.2 and 59.3% by Xpert, 35.5 and 61.5% by MGIT,
and 22.6% and 38.7 by viable colony counts (Table S1). All
median values reflected decreased bacillary load over time,
with increasing Xpert Ct and MGIT TTP; and decreasing
viable counts (Fig. 3a, b and c respectively, Table S2). A
requirement for EBA studies is a serial quantifiable meas-
ure of mycobacterial load to determine response to drug
therapy [22]. The EBA values for smear-negative and
smear-positive groups were − 0.21 logCFU/ml/day and −
0.29 logCFU/ml/day, respectively until day 7. The bacterial
load at baseline in the smear-negative patients is thus suf-
ficient to allow for comparison of clearance upon drug
treatment.
Discussion
We compared a cohort of smear-negative and smear-
positive PLH for their initial bacterial burden and early
treatment responses. Severity of lung cavitation corre-
sponded with baseline bacterial load, as expected [4].
While all measures of initial bacterial burden in the
smear-positive was higher than the smear-negative pa-
tients, bacillary decline was able to be measured in both
groups that were positive on subsequent measures. Our
data suggest that, overall, 90% of HIV-infected adults di-
agnosed by Xpert alone, irrespective of smear status,
would have a simultaneous positive MGIT culture result,
and the majority of these could have serial measures of
bacillary load whilst taking treatment.
Although most smear-negative patients were baseline
culture positive (85.2% by MGIT and 79.2% by Xpert),
this was lower than in smear-positive patients (96.9% by
MGIT and 90.8% by Xpert); baseline bacterial load of
smear-negative patients was 1.61 fold lower than that of
the smear-positive group and bacteria were cleared in
Fig. 1 Comparison at enrolment of Xpert threshold values (Ct)
against bacterial load as determined by smear microscopy status.
Dark blue squares, AUNEG; dark red triangles, AUSC; red inverted
triangles, AUP1+; orange diamonds, AUP2+; blue circles, AUP3+,
green hexagons, AUPOS (AUSC, AUP1+, AUP2+ and AUP3+)
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less than half the time in smear-negative patients, com-
pared to smear-positive. Indeed, by day 14 MGIT TTP
values approached 42 days in smear-negative patients.
Our data also suggest that smear-negative TB patients
may benefit from shortened treatment regimens [23, 24].
Moreover, serial bacterial counts in this early treatment
period may be clinically relevant to rapidly identify pa-
tients not responding well to TB treatment. Xpert tests
are increasingly available in clinical settings and could
be used to quantify declines in bacillary load in practice,
particularly in those who are smear-positive or have a
low Ct value at baseline. Ct values of the smear-negative
group did not change during treatment, because they
reached the limit of detection (26.8 to 27.8, Fig. 3a). In
the smear-positive group serial Ct values started lower
and increased by day 14 (18.7 to 20.6), suggesting that at
least in smear-positive patients or those with an initial
low Ct value the Xpert assay has potential for rapidly
identifying TB patients who are not responding to ther-
apy. However, a substantial proportion (31.4%) of smear-
negative patients had a negative Xpert test at baseline.
As a group, most smear-negative patients included in
this study had sufficient viable bacteria that could be
analysed meaningfully up to day 14 but one third of the
smear-negative patients were also Xpert negative at
baseline. MGIT tests have been reported to be at least
equally as sensitive as colony counts [25–27] and we
found at least 80% of smear-negative patients were cul-
ture positive at baseline.
There were several limitations to our study. This was a
three-site study from one country; we did not document
adherence of tuberculosis treatment or antiretroviral
therapy; missing laboratory values and losses to follow
up may have biased our results. The Xpert Ultra has
largely replaced the assay we used to determine declines
in bacterial load in this study. The sample size was small
and we had fewer smear-negative patients in our ana-
lyses than we originally anticipated, and thus were un-
able to model the site effect. Moreover, apart from
documenting the proportion of culture negative smear-
negative PLH, we did not model sample size and cost
implications of late exclusions of smear-negative TB pa-
tients from clinical trials who are subsequently found to
be culture negative.
Conclusion
Our data suggest that treatment responses in smear-
negative HIV-infected TB patients whose initial positive
diagnostic test was Xpert are measurable in most pa-
tients, suggesting that smear-negative PLH could be in-
cluded in trials of novel TB therapies. Serial Xpert
testing reflects treatment responses and could be a use-
ful real-time measure of treatment response, but more
research is required to ascertain if this holds true with
Fig. 2 Percentage positivity for patient smear-positive (red curves) and smear-negative (blue curves) patient groups up to day 35. Results were
based on a smear status, b Xpert, c MGIT and d viable counts
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the Xpert Ultra and to determine if serial measures
could predict long term TB treatment outcomes. HIV-
infected smear-negative patients can be included in
clinical trials provided sample sizes are adjusted upwards
for those that are eventually found to be culture
negative.
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